Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
275M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
167M
-
Shares change
-
-609K
-
Total reported value, excl. options
-
$232M
-
Value change
-
-$5.17M
-
Put/Call ratio
-
0.07
-
Number of buys
-
59
-
Number of sells
-
-54
-
Price
-
$1.39
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q1 2025
151 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q1 2025.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 167M shares
of 275M outstanding shares and own 60.69% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (20M shares), RTW INVESTMENTS, LP (18.8M shares), MORGAN STANLEY (16.8M shares), FMR LLC (15.6M shares), BlackRock, Inc. (13.6M shares), RA CAPITAL MANAGEMENT, L.P. (10.9M shares), Octagon Capital Advisors LP (10.7M shares), VANGUARD GROUP INC (8.77M shares), Siren, L.L.C. (6.51M shares), and Point72 Asset Management, L.P. (4.57M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.